| Cas No.: | 1072874-90-8 |
| Chemical Name: | Miravirsen |
| Synonyms: | Miravirsen;Miravirsen [INN];SPC3649 Parent Acid;Q083AJW7VS;RNA, (P-thio)((2'-O,4'-C-methylene)m5C-dC-(2'-O,4'-C-methylene)A-dT-dT-(2'-O,4'-C-methylene)G-(2'-O,4'-C-methylene)m5U-dC-dA-(2'-O,4'-C-methylene)m5C-dA-(2'-O,4'-C-methylene)m5C-dT-(2'-O,4'-C-methylene)m5C-(2'-O,4'-C-methylene)m5C) |
| SMILES: | S=P(O)(OCC12COC(C(N3C(NC(C(C)=C3)=O)=O)O1)C2OP(O)(OCC1C(CC(N2C(N=C(C=C2)N)=O)O1)OP(O)(OCC1C(CC(N2C=NC3C(N)=NC=NC2=3)O1)OP(O)(OCC12COC(C(N3C(N=C(C=C3)N)=O)O1)C2OP(O)(OCC1C(CC(N2C=NC3C(N)=NC=NC2=3)O1)OP(O)(OCC12COC(C(N3C(N=C(C=C3)N)=O)O1)C2OP(O)(OCC1C(CC(N2C(NC(C(C)=C2)=O)=O)O1)OP(O)(OCC12COC(C(N3C(N=C(C=C3)N)=O)O1)C2OP(O)(OCC12COC(C(N3C(N=C(C=C3)N)=O)O1)C2O)=S)=S)=S)=S)=S)=S)=S)=S)OC1C2C(N3C=NC4C(NC(N)=NC3=4)=O)OC1(COP(O)(OC1CC(N3C(NC(C(C)=C3)=O)=O)OC1COP(O)(OC1CC(N3C(NC(C(C)=C3)=O)=O)OC1COP(O)(OC1C3C(N4C=NC5C(N)=NC=NC4=5)OC1(COP(O)(OC1CC(N4C(N=C(C=C4)N)=O)OC1COP(O)(OC1C4C(N5C(N=C(C=C5)N)=O)OC1(CO)CO4)=S)=S)CO3)=S)=S)=S)CO2 |
| Formula: | C151H185N49O83P14S14 |
| M.Wt: | 4896.90576338768 |
| Purity: | >95% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Target: | miR-122 |
| In Vivo: | Miravirsen (SPC-3649; 2.5-25 mg/kg; i.v.; daily, for 3 d) inhibits miR-122 activity in mice |
| In Vitro: | Miravirsen is thought to work mainly by hybridizing to mature miR-122 and blocking its interaction with HCV RNA, its target sequence is also present in pri- and pre-miR-122. Miravirsen binds to the stem-loop structure of pri- and pre-miR-122 with nanomolar affinity, and inhibits both Dicer- and Drosha-mediated processing of miR-122 precursors |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|